Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):207–210. doi: 10.1128/aac.28.2.207

Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus.

F E Berkowitz, M J Levin
PMCID: PMC180220  PMID: 3010838

Abstract

An in situ enzyme-linked immunosorbent assay (ELISA), performed directly on fixed varicella-zoster virus-infected monolayers, was used to quantitate viral antigen, and by color reduction it was used to evaluate the activity of drugs against varicella-zoster virus. Color production in the ELISA (optical density) was directly related to the dose of input virus. Antigen representing 5 to 10 plaques could be detected 3 days after infection. The ELISA was specific and reproducible, as shown by absorption and repeat experiments, respectively. A color-reduction test by ELISA was compared with the conventional plaque-reduction assay for its ability to measure the antiviral activity of acyclovir, bromovinyldeoxyuridine, trifluorothymidine, and vidarabine against four strains of varicella-zoster virus. In all cases but one the 50% inhibitory doses were lower when measured by ELISA than by the plaque-reduction assay. This in situ ELISA color reduction method had the following advantages over the conventional plaque-reduction assay: the endpoint was an objective measurement; there was less well-to-well variation; the assay was sensitive to changes in plaque size as well as plaque number; it was less labor intensive.

Full text

PDF
207

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J., Rowe L. W. The use of an enzyme-labelled assay as an aid to reading micro virus-neutralisation tests. J Immunol Methods. 1982 Sep 17;53(2):183–186. doi: 10.1016/0022-1759(82)90139-9. [DOI] [PubMed] [Google Scholar]
  2. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Clercq E., Descamps J., Ogata M., Shigeta S. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother. 1982 Jan;21(1):33–38. doi: 10.1128/aac.21.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harmenberg J., Wahren B., Oberg B. Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology. 1980;14(5-6):239–244. doi: 10.1159/000149192. [DOI] [PubMed] [Google Scholar]
  6. Hermodsson S., Strannegård O., Jeansson S. Bioimmunoassays (BIAs) of human interferon. Proc Soc Exp Biol Med. 1984 Jan;175(1):44–51. doi: 10.3181/00379727-175-41764. [DOI] [PubMed] [Google Scholar]
  7. Machida H., Kuninaka A., Yoshino H. Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus. Antimicrob Agents Chemother. 1982 Feb;21(2):358–361. doi: 10.1128/aac.21.2.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nilheden E., Jeansson S., Vahlne A. Typing of herpes simplex virus by an enzyme-linked immunosorbent assay with monoclonal antibodies. J Clin Microbiol. 1983 Apr;17(4):677–680. doi: 10.1128/jcm.17.4.677-680.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Preblud S. R., Arbeter A. M., Proctor E. A., Starr S. E., Plotkin S. A. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds. Antimicrob Agents Chemother. 1984 Apr;25(4):417–421. doi: 10.1128/aac.25.4.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shehab Z., Brunell P. A. Enzyme-linked immunosorbent assay for susceptibility to varicella. J Infect Dis. 1983 Sep;148(3):472–476. doi: 10.1093/infdis/148.3.472. [DOI] [PubMed] [Google Scholar]
  11. Shigeta S., Yokota T., Iwabuchi T., Baba M., Konno K., Ogata M., De Clercq E. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis. 1983 Mar;147(3):576–584. doi: 10.1093/infdis/147.3.576. [DOI] [PubMed] [Google Scholar]
  12. Zhang Y. H., Yu W. F., Tian Z. W., Ge J. Q., Chen Q. S., Wang Y. M. A simplified new method for the identification of arboviruses: virus detection using enzyme immunoassay on cultured cells. J Virol Methods. 1984 Aug;9(1):45–51. doi: 10.1016/0166-0934(84)90082-x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES